Celltrion Pharm, Inc.
Financials
Valuation Metrics
Celltrion Pharm, Inc.'s Market Cap is ₩1.7T. At end of 2025 it was ₩2.6T. Ranked #233 of 2,421 in KR market (top 10%), #52 of 1,640 on KOSDAQ (top 3%), #22 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 10%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.72T KRW | KR#233/2,421 Sec#22/231 |
| Revenue | 577.99B KRW | KR#573/2,421 Sec#28/231 |
| Net Income | 42.88B KRW | KR#468/2,421 Sec#29/231 |
| Total Assets | 779.18B KRW | KR#565/2,421 Sec#32/231 |
| Net Assets | 449.20B KRW | KR#553/2,421 Sec#33/231 |
| Employees | 920 | KR#277/2,421 Sec#22/231 |
| Value | ||
| P/E | 40.18x | KR#1,379/2,421 Sec#85/231 |
| P/B | 3.84x | KR#2,180/2,421 Sec#178/231 |
| PEG | 1.32x | KR#765/2,421 Sec#49/231 |
| P/S | 2.98x | KR#1,979/2,421 Sec#123/231 |
| EV/EBITDA | 29.22x | KR#1,186/2,421 Sec#74/231 |
| FCF Yield | 4.08% | KR#912/2,421 Sec#54/231 |
| Profitability | ||
| ROE | 9.55% | KR#653/2,421 Sec#45/231 |
| ROA | 5.50% | KR#680/2,421 Sec#56/231 |
| Op. Margin | 10.73% | KR#480/2,421 Sec#43/231 |
| Revenue Growth | 13.88% | KR#725/2,421 Sec#71/231 |
| Earnings Growth | 30.36% | KR#645/2,421 Sec#43/231 |
| Financial Health | ||
| Debt Ratio | 73.46% | KR#1,262/2,421 Sec#151/231 |
| Total Debt | 142.00B KRW | KR#619/2,421 Sec#35/231 |
| FCF | 70.27B KRW | KR#238/2,421 Sec#14/231 |
| Cash | 51.70B KRW | KR#716/2,421 Sec#40/231 |
| Current Ratio | 1.71x | KR#1,026/2,421 Sec#115/231 |
| Net Debt/EBITDA | 1.46x | KR#785/2,421 Sec#54/231 |
| Dividend | ||
| Div. Yield | 0.50% | KR#1,262/2,421 Sec#77/231 |
| Performance | ||
| 1Y Return | -26.18% | KR#1,440/2,421 Sec#105/231 |
| 1M Return | -5.71% | KR#1,849/2,421 Sec#149/231 |
| From 52W High | -50.45% | KR#1,416/2,421 Sec#109/231 |
| 1Y MDD | -49.80% | KR#981/2,421 Sec#81/231 |
| Trading | ||
| Volume | 149,937 shares | KR#593/2,421 Sec#46/231 |
| Trading Value | 5.81B KRW | KR#344/2,421 Sec#30/231 |
| Foreign Own. | 4.83% | KR#882/2,421 Sec#79/231 |
| Per Share | ||
| EPS | 966 KRW | KR#734/2,421 Sec#50/231 |
| BPS | 10,117 KRW | KR#990/2,421 Sec#69/231 |
Company Info
This specialized pharmaceutical manufacturing and sales company was established in 2000 and listed on KOSDAQ in 2006. It operates KGMP, US cGMP, and EU-GMP certified facilities in Ochang and Jincheon, Chungcheongbuk-do, producing specialized pharmaceuticals and biopharmaceuticals via PFS production lines. The company holds domestic exclusive sales rights for chemical pharmaceuticals like the liver disease treatment Godex, and 12 biopharmaceuticals, including autoimmune disease treatments and anti-cancer drugs developed by its parent company, Celltrion, while actively pursuing pipeline expansion and technological platform innovation.